Evidence map›Paper›PMID 28315708›Full record

ArticleAntiviral research2017

2016 International meeting of the Global Virus Network.

Ramesh Akkina, Heinz Ellerbrok, William Hall, Hideki Hasegawa, Yasushi Kawaguchi, Harold Kleanthous, Edward McSweegan, Natalia Mercer, Victor Romanowski, Hirofumi Sawa and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 6 countries.

Ramesh AkkinaDepartment of Microbiology, Immunology & Pathology, Colorado State University, Ft. Collins, CO, USA.
Heinz EllerbrokCentre for Biological Threats and Special Pathogens, Robert Koch-Institute, Berlin, Germany.
William HallDepartment of Medical Microbiology, University College, Dublin, Ireland.
Hideki HasegawaNational Institute of Infectious Diseases, Tokyo, Japan.
Yasushi KawaguchiDepartment of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Harold KleanthousDiscovery Research, Sanofi-Pasteur, Boston, MA, USA.
Edward McSweeganGlobal Virus Network, Baltimore, MD, USA. Electronic address: emcsweegan@gvn.org.
Natalia MercerGlobal Virus Network, Baltimore, MD, USA.
Victor RomanowskiInstitute of Biotechnology & Molecular Biology, Universidad Nacional de La Plata, Argentina.
Hirofumi SawaDivision of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Anders VahlneDepartment of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
Global Virus Network · USColorado State University · USHokkaido University · JPKarolinska Institutet · SENational Institute of Infectious Diseases · JPRobert Koch Institute · DESanofi (United States) · USThe University of Tokyo · JPUniversidad Nacional de La Plata · ARUniversity College Dublin · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Global Virus Network (GVN) was established in 2011 in order to strengthen research and responses to current viral causes of human disease and to prepare against new viral pandemic threats. There are now 38 GVN Centers of Excellence and 6 Affiliate laboratories in 24 countries. GVN scientists meet annually to learn about each other's current research, address collaborative priorities and plan future programs. The 2016 meeting was held from October 23-25 in Hokkaido, Japan, in partnership with the Japanese Society for Virology, the National Institute of Infectious Diseases of Japan and the Research Center for Zoonosis Control of Hokkaido University. This report highlights the accomplishments of GVN researchers in many priority areas of medical virology, including the current Zika epidemic, infections by human papillomavirus, influenza, Ebola, Lassa, dengue, HIV, hepatitis C, and chikungunya viruses, and the development of improved diagnostics and new vaccines.

Indexed as

International CooperationAnimalsCommunicable DiseasesCongresses as TopicDisease OutbreaksEpidemiological MonitoringGlobal HealthHumansJapanPandemicsResearchVirusesZoonosesEmerging virusesGlobal Virus NetworkInternational collaborationsMedical virology

Identifiers

PMID28315708
PMCPMC7113740
OpenAlexW2917604483

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.